Join us in building the pharmaceutical infrastructure for the next generation of psychedelic treatments.
Contact Investor RelationsAERASYN Biotech is positioned to lead the emerging psychedelic medicine sector with a differentiated platform approach.
The global mental health market exceeds $500B, with psychedelic-assisted therapy poised to capture significant share in treatment-resistant conditions.
Our vertically integrated five-pillar platform creates sustainable competitive advantages across the entire drug development lifecycle.
Strategic collaborations with leading universities in Canada and Europe provide access to world-class research and clinical expertise.
5
Platform Pillars
2+
Academic Partnerships
100+
Years Combined Experience
Unlike traditional psychedelic companies focused on single molecules, we've built a vertically integrated platform that addresses the entire drug development lifecycle.
Vertically Integrated
Discovery through commercialization
Precision Delivery
Controlled-release systems
Engineered Modulation
Non-hallucinogenic compounds
AI-Powered Development
Accelerated discovery
Single Molecule Focus
Limited pipeline expansion
Clinic Dependent
Relies on third-party infrastructure
High Hallucinogenic Risk
Safety concerns limit dosing
Scalability Challenges
Manufacturing bottlenecks
Built during the down cycle—capital efficient, strategically positioned, and ready to capture the psychedelic medicine opportunity.
Capital Efficient Structure
Built during the down cycle with lean operations and strategic spending.
Strong IP Portfolio
21 patents across discovery, delivery, and manufacturing.
Vertically Integrated
End-to-end platform reduces dependence on third parties.
Multiple Value Pathways
Licensing, co-development, and acquisition options.
We welcome conversations with institutional investors, venture capital firms, and strategic partners interested in the future of psychedelic medicine.
Investor Inquiries
[email protected]